ASCO 2020：11项中国研究入选口头调查结果，17项Poster调查结果

受全球原先冠疫情影响，原定于5年初29日~6年初2日在芝加哥举办的美国医学学则会（ASCO）年则会月份将首次以线上形式举办，这是目前最大规模的线上盛则会。以前，全体则会议的内容可题目公布，总共103个sessions，中则会国总共有11项分析跻身口头报告，17项跻身Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨常用HER2+丙型肝炎乳腺乳癌（PHOEBE）：一项III期随机飞行测试。

首站：丙型肝炎乳腺乳癌

译者：中则会国医学科学院诊所徐兵河讲师、马飞讲师，上海交通大学附属诊所胡夕春讲师等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴功能性乳腺乳癌标准疗程后卡培他滨维持节拍中风的III期飞行测试（SYSUCC-001）。

首站：乳腺乳癌—角化/范围内/辅助疗程

译者：中则会山大学防治中则会心王树森讲师等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

借助丙型肝炎脑的表型特质来得出脑脊液中则会循环DNA检测的概率: 原先工具箱对抗老劲敌

首站：原先工具箱应付老难题

译者：陈美芹 陈堪等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为早期肝蛋白乳癌的中路疗程：一项闭馆页面、随机、多中则会心II/III期飞行测试。

首站：腹腔肠道乳癌—腹腔冠状动脉、胰腺和实乃

译者：武汉大学棱果诊所毕锋讲师、武警八一诊所秦叔逵讲师等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中则会国早期肝乳癌病征阿帕替尼二线疗程：一项随机、安慰剂对照、双盲III期分析

首站：腹腔肠道乳癌—腹腔冠状动脉、胰腺和实乃

译者：武警八一诊所秦叔逵讲师、武汉大学棱果诊所陈秋讲师等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期乳头状卵巢乳癌二次蛋白减灭术的一项随机III期飞行测试：SOC1 / SGOG-OV2。

回顾：诊疗乳乳癌

译者：上海交通大学附属中则会山诊所臧荣余讲师等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治功能性子宫切除术后辅助疗程中则会的序贯放中风对比之外MRI或同步放中风（STARS分析）：一项随机、对照、闭馆页面的III期飞行测试。

全体则会议：诊疗乳乳癌

译者：中则会山大学防治中则会心黄鹤讲师、刘继红讲师等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比中风常用可切除的EGFR基因突变的N1-N2期NSCLC-随机III期医学飞行测试的最后总体生存分析方法。

回顾：乳乳癌—非小蛋白角化-范围内/小蛋白/其他颈部

译者：广东省人民诊所吴一龙讲师等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因突变寡转移非小蛋白乳乳癌病征中路组氨酸趋化因子胺牵头或不牵头努力前线角化MRI：III期闭馆页面医学随机飞行测试（SINDAS）的中则会期结果（NCT02893332）。

回顾：乳乳癌-非小蛋白转移

译者：广元市人民诊所曾铭讲师等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对就其死亡-1（PD-1）的人源化IgG4化学合成牵头阿昔替尼常用丙型肝炎口腔阿兹海默病征的Ib期分析的总生存期和生物一个大分析方法。

回顾：阿兹海默/皮肤乳癌

译者：北大诊所郭军、盛锡楠讲师等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可用功能性和结果：国际标准CAR-T蛋白首次人体飞行测试疗程中风/难治功能性T蛋白急功能性淋巴蛋白白血病（r/r T-ALL）的可用功能性和。全体则会议：研发中则会的疗程技术-免疫疗程。译者：王欣欣等内容可：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在早期冠状动脉鳞状蛋白乳癌病征中则会的应用：一项随机的闭馆页面II期飞行测试（ORIENT-2）。全体则会议：腹腔肠道乳癌-腹腔冠状动脉乳癌、胰腺乳癌和实乃道乳癌译者：徐建明讲师等内容可：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异功能性CAR-T蛋白对肾母蛋白瘤的根治功能性疗程全体则会议：中则会枢神经系统译者：代红久、孙斌、杨东、徐晖、杨晶晶、魏佳、赵旭东内容可：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复缺陷病征中则会的应用全体则会议：研发中则会的疗程学-免疫疗程译者：沈琳讲师等内容可：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART疗程中风/难治功能性ACUTE淋巴蛋白白血病/淋巴瘤的首例人体医学飞行测试全体则会议: 研发功能性疗程学-免疫疗程译者简介：张明志，杨林等内容可：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）牵头应常用早期实体瘤病征的Ib期分析全体则会议：发展功能性疗程学--分子靶向制剂和生物学译者：龚继芳，沈琳讲师等内容可：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin牵头紫杉醇和nedaplatin疗程乳头状或丙型肝炎冠状动脉鳞状蛋白乳癌（ESCC）病征的II期分析。全体则会议：腹腔肠道乳癌-腹腔冠状动脉、胰腺和实乃道乳癌的分析译者：王志强，陈玉红，王德申，王凤华，任超，谭琼 王志强、陈玉红、王德深、王凤华、任超、谭琼内容可：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体则会议：腹腔肠道乳癌-腹腔冠状动脉乳癌、胰腺乳癌和实乃管乳癌的二线疗程译者：宋艳等内容可：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血浆外体放射状RNA方差常用初始解剖时检测高等级乳癌的血浆外体放射状RNA方差：一项多中则会心的回顾功能性分析全体则会议：泌尿生殖系统乳乳癌---乳癌、睾丸乳癌和乳癌译者简介：Liaoyuan Li等内容可：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 角化早期宫颈乳癌即刻中风后的辅助中风全体则会议: 诊疗乳乳癌译者简介： 陈珉珉等内容可：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗程骨髓肾功能性乳癌的相似功能性：基于ALTER01031飞行测试的分析方法。则会话里：躯干译者：沈阳市诊所高深讲师内容可：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗程后病征结局的影响: ALTER01031的亚组分析方法全体则会议：躯干译者：沈阳市诊所高深讲师内容可：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法得出I-IIIA期非小蛋白乳乳癌（NSCLC）病征术后中风: GASTO1035和GASTO1018的结果全体则会议：乳乳癌-非小蛋白角化-范围内功能性/小蛋白/小蛋白/其他胸科乳乳癌译者：Si-Yu Wang等内容可：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白乳乳癌（NSCLC）中则会EGFR组氨酸趋化因子胺的原先型病毒功能性必要全体则会议:乳乳癌-非小蛋白丙型肝炎乳乳癌译者简介：赵昕，金大姐，满宇，欧秋香，华宝，薛武，杨少，范敏 赵昕、金大姐、满宇、欧秋香、华宝、薛武、杨绍、范敏内容可：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1飞行测试中则会早期阿兹海默总生存的替代西端全体则会议：阿兹海默/皮肤乳癌译者：聂润聪，袁书强，陈元芳，陈英波，周志伟 聂润聪、袁书强、陈元芳、陈英波、周志伟内容可：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗程中风或丙型肝炎原发功能性恶功能性头骨病征的II期分析全体则会议： 恶功能性肿瘤译者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、朝臣、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步高度评价安罗替尼在早期恶功能性肿瘤病征多线疗程中则会的可用功能性和。全体则会议：恶功能性肿瘤译者：姚伟涛，王家强，张鹏，王欣，杜原先辉，田志浩，牛晓颖 姚伟涛、王家强、张鹏、王鑫、杜鑫辉、田志超、牛晓英内容可：11526广告：414